NT-219 Re-sensitizes Cancer to Keytruda, Stopping Tumor Progression, Study Shows

by Alice Melão

Adding TyrNovo‘s NT-219 to Merck’s Keytruda (pembrolizumab) converted Keytruda-resistant tumors into therapy responders, stopping tumor progression, a study reports.

The research, which involved a number of cancers, was a collaboration between Bar Ilan University and Rabin Medical Center in the Tel Aviv area and the Israeli pharmaceutical company TyrNovo, a subsidiary of Tel Aviv-based Kitov Pharmaceuticals Holdings.

NT-219 targets proteins known as insulin receptor substrates that play a role in cancer developing resistance to drugs.

TyrNovo designed NT-219 to re-sensitize cancer cells to standard therapies, restoring the therapies’ punch.

The study showed that a combination of NT-219 and Keytruda reversed the resistance that mice with esophagus cancer had developed to Keytruda. Neither NT-219 nor Keytruda was able to combat the cancer alone, but the combo therapy inhibited tumor progression, researchers said.

“We are excited with these initial results obtained with NT-219 in combination with pembrolizumab (Keytruda),” Dr. J. Paul Waymack, Kitov’s board chairman, said in a press release.

“Previous results obtained with NT-219 demonstrated its efficacy in overcoming drug resistance in a variety of cancers and in combination with various pharmacologic cancer therapies,” Waymack said.

In previous studies, researchers demonstrated that combining NT-219 with Tarceva (erlotinib) led to significant head and neck cancer regression, and prevented tumors from becoming resistant to Tarceva.

Similarly, a combination of NT-219 and Erbitux (cetuximab) significantly delayed the recurrence of this type of cancer.

NT-219 also promoted melanoma regression when combined with Zelboraf (vemurafenib) and Mekinist (trametinib). This combo was able to generate responses even in metastatic melanoma that had acquired resistance to Zelboraf and Mekinist.

In addition, NT-219 has demonstrated therapeutic potential when combined with Afinitor (everolimus) as a treatment for uterine adenosarcoma, an aggressive cancer with no approved therapies. The combo triggered a complete response in 40 percent of the animals treated with it. And they remained tumor-free for more than three months after the therapy ended.

“We are focused on advancing this highly promising therapeutic candidate to clinical trials as quickly as possible in order to provide enhanced treatment options to cancer patients,” Waymack said.